Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Tango Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.15%, while the net margin is 29.52%. These profitability ratios, combined with a Return on Equity (ROE) of -51.65%, provide a clear picture of how effectively TNGX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TNGX competes directly with industry leaders such as ANAB and TRVI. With a market capitalization of $1.50B, it holds a significant position in the sector. When comparing efficiency, TNGX's gross margin of 100.00% stands against ANAB's 100.00% and TRVI's N/A. Such benchmarking helps identify whether Tango Therapeutics Inc is trading at a premium or discount relative to its financial performance.
